Allergen-specific IgG antibodies against Phleum pratense pollen proteins (Phl p-specific IgG)

Allergen-specific IgG antibodies against Phleum pratense pollen proteins, particularly the IgG4 subclass, are key immunological mediators induced during allergen immunotherapy (AIT) for Timothy grass allergy [1.3.1, 1.3.4]. These antibodies function as "blocking antibodies" by competing with allergen-specific IgE for binding to major Timothy grass allergens such as Phl p 1 and Phl p 5 [1.2.1, 1.2.4]. By preventing the formation of allergen-IgE complexes, they inhibit the cross-linking of high-affinity IgE receptors (FcεRI) on mast cells and basophils, thereby suppressing the release of inflammatory mediators like histamine and cytokines [1.1.1, 1.3.4]. In clinical practice, the induction of these IgG antibodies is a primary therapeutic objective of sublingual (SLIT) and subcutaneous (SCIT) immunotherapy products like Grazax and Oralair [1.4.1]. Beyond their role as effectors, serum levels of Phl p-specific IgG4 serve as essential biomarkers for monitoring the efficacy and immunological progress of AIT [1.2.1, 1.3.1]. Furthermore, research into passive immunization suggests that the direct administration of these antibodies could provide immediate protection against allergic reactions, highlighting their potential as both a therapeutic product and a target of immune modulation [1.1.1].

Other names

Timothy grass-specific IgGPhl p-specific IgG4Blocking antibodies against Phleum pratenseGrass pollen-specific IgGTimothy grass-specific IgG4

Induction of allergen-specific IgG4 antibodies that compete with IgE for allergen binding, thereby inhibiting IgE-mediated mast cell and basophil degranulation.